Related Experiment Video
Updated: Aug 17, 2026
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Multisite phosphotyping of the ErbB-2 oncoprotein in human breast cancer
X Ouyang1, T Gulliford, G C Huang
1Division of Investigative Sciences, Imperial College School of Medicine, London, UK.
Background:
Overexpression of the ErbB-2 (HER2/neu) receptor tyrosine kinase is one of the most common molecular changes in human cancer, but the functional significance of this phenotype remains uncertain.
Methods And Results:
Using phosphorylation-specific antibodies recognizing different ErbB-2 functional states, we assessed the phosphorylation status of ErbB-2 in 102 human breast cancer specimens. Quantitative ErbB-2 immunoblotting intensity correlated directly with that of immunohistochemistry (r = 0.84). Widely varying phosphorylation profiles were evident in 65 ErbB-2-positive carcinomas, suggesting different ErbB-2 functions in different tumors. In a subset of patients for whom clinical data were obtainable, mortality trends were strongly associated with the quantitative signal intensities of ErbB-2 phosphoantibodies (P < or =.02), but not with those of conventional antibodies to ErbB-2 (P = .147), epidermal growth factor receptor (P = .44), or phosphotyrosine (P = .94).
Conclusion:
Although requiring corroboration in larger prospective clinical studies, these findings suggest that immunophenotyping using phosphorylation-specific antibodies may enable more accurate prediction of cancer behavior than is currently obtainable using conventional reagents.
Insights
Phosphorylation-specific antibodies reveal varied ErbB-2 functional states in breast cancer, with specific phosphoantibody signals predicting mortality trends. This suggests a more accurate cancer behavior prediction method than conventional reagents.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Overexpression of the ErbB-2 (HER2/neu) receptor tyrosine kinase is a common molecular alteration in human cancers.
- The precise functional significance of ErbB-2 overexpression in cancer progression remains incompletely understood.
- Understanding ErbB-2's role is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To investigate the functional significance of ErbB-2 overexpression in human breast cancer.
- To assess the phosphorylation status of ErbB-2 in breast cancer specimens using phosphorylation-specific antibodies.
- To correlate ErbB-2 phosphorylation profiles with clinical data and patient mortality.
Main Methods:
- Utilized phosphorylation-specific antibodies to analyze ErbB-2 functional states in 102 human breast cancer specimens.
- Performed quantitative ErbB-2 immunoblotting and correlated results with immunohistochemistry.
- Examined mortality trends in relation to ErbB-2 phosphoantibody signal intensities and conventional antibody data.
Main Results:
- Quantitative ErbB-2 immunoblotting intensity showed a strong correlation with immunohistochemistry (r = 0.84).
- Diverse ErbB-2 phosphorylation profiles were observed in ErbB-2-positive carcinomas, indicating varied functional roles.
- Mortality trends were significantly associated with quantitative ErbB-2 phosphoantibody signals (P ≤ .02), but not with conventional ErbB-2 or other markers.
Conclusions:
- Immunophenotyping with phosphorylation-specific antibodies may offer superior prediction of cancer behavior compared to conventional methods.
- These findings highlight the potential of targeting specific ErbB-2 functional states for improved cancer management.
- Further validation in larger prospective clinical studies is warranted to confirm these promising results.
